[1] Flores A,Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol,2014,8:71-76.
[2] 赵泽华,范建高. 2016年美国肝病年会非酒精性脂肪性肝病深度报道. 实用肝脏病杂志, 2017,20:21-24.
[3] Kikuchi L,Oliveira CP,Alvaresda-Silva MR,et al. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. Am J Clin Oncol,2016,39:428-432.
[4] 徐燕华,欧强. 非酒精性脂肪性肝炎相关肝细胞癌研究进展. 肝脏,2016,21:1074-1076.
[5] Bruix J,Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology,2011, 53:1020-1022.
[6] Weinmann A,Alt Y,Koch S,et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer,2015,15: 210.
[7] Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol,2014,20:12945-12955.
[8] 张静怡,李春敏,唐颖悦,等. 非酒精性脂肪性肝病对肠道炎症及通透性的影响. 肝脏, 2017,22:219-223.
[9] El-Serag HB. Hepatocellular carcinoma. N Engl J Med,2011,365:1118-1127.
[10] Cauchy F,Zalinski S,Dokmak S,et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg,2013,100:113-121.
[11] Reeves H,Villa E,Bellentani S,et al. The emerging impact of hepatocellular carcinoma arising on a background of NAFLD. J Hepatol,2012,56:S3.
[12] Cotrim HP, Parana R, Braga E, et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol, 2000,95:3018-3019. |
